RhumbLine Advisers’s Evolent Health EVH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $855K | Buy |
157,823
+5,253
| +3% | +$20.1K | ﹤0.01% | 2415 |
|
|
2026
Q1 | $348K | Sell |
152,570
-4,216
| -3% | -$13.4K | ﹤0.01% | 2831 |
|
|
2025
Q4 | $627K | Sell |
156,786
-23,400
| -13% | -$130K | ﹤0.01% | 2534 |
|
|
2025
Q3 | $1.52M | Sell |
180,186
-5,679
| -3% | -$55.1K | ﹤0.01% | 2049 |
|
|
2025
Q2 | $2.09M | Buy |
185,865
+15,947
| +9% | +$146K | ﹤0.01% | 1861 |
|
|
2025
Q1 | $1.61M | Buy |
169,918
+3,527
| +2% | +$35.6K | ﹤0.01% | 1929 |
|
|
2024
Q4 | $1.87M | Sell |
166,391
-3,749
| -2% | -$65.9K | ﹤0.01% | 1918 |
|
|
2024
Q3 | $4.81M | Sell |
170,140
-9,919
| -6% | -$256K | ﹤0.01% | 1443 |
|
|
2024
Q2 | $3.44M | Buy |
180,059
+13,867
| +8% | +$354K | ﹤0.01% | 1603 |
|
|
2024
Q1 | $5.45M | Buy |
166,192
+4,128
| +3% | +$132K | 0.01% | 1375 |
|
|
2023
Q4 | $5.35M | Sell |
162,064
-2,125
| -1% | -$60.1K | 0.01% | 1363 |
|
|
2023
Q3 | $4.47M | Buy |
164,189
+2,157
| +1% | +$60K | 0.01% | 1425 |
|
|
2023
Q2 | $4.91M | Buy |
162,032
+44,112
| +37% | +$1.43M | 0.01% | 1383 |
|
|
2023
Q1 | $3.83M | Sell |
117,920
-394
| -0.3% | -$12.5K | ﹤0.01% | 1462 |
|
|
2022
Q4 | $3.32M | Buy |
118,314
+4,574
| +4% | +$131K | ﹤0.01% | 1528 |
|
|
2022
Q3 | $4.09M | Buy |
113,740
+8,988
| +9% | +$317K | 0.01% | 1351 |
|
|
2022
Q2 | $3.22M | Sell |
104,752
-2,824
| -3% | -$82.3K | ﹤0.01% | 1498 |
|
|
2022
Q1 | $3.48M | Sell |
107,576
-8,234
| -7% | -$216K | ﹤0.01% | 1540 |
|
|
2021
Q4 | $3.2M | Sell |
115,810
-539
| -0.5% | -$15.5K | ﹤0.01% | 1614 |
|
|
2021
Q3 | $3.61M | Buy |
116,349
+2,699
| +2% | +$64.8K | ﹤0.01% | 1556 |
|
|
2021
Q2 | $2.4M | Sell |
113,650
-13,606
| -11% | -$273K | ﹤0.01% | 1864 |
|
|
2021
Q1 | $2.57M | Sell |
127,256
-8,670
| -6% | -$165K | ﹤0.01% | 1788 |
|
|
2020
Q4 | $2.18M | Buy |
135,926
+13,817
| +11% | +$183K | ﹤0.01% | 1808 |
|
|
2020
Q3 | $1.51M | Sell |
122,109
-16,379
| -12% | -$193K | ﹤0.01% | 1824 |
|
|
2020
Q2 | $986K | Buy |
138,488
+14,480
| +12% | +$97K | ﹤0.01% | 2053 |
|
|
2020
Q1 | $673K | Buy |
124,008
+10,676
| +9% | +$95.4K | ﹤0.01% | 2043 |
|
|
2019
Q4 | $1.03M | Buy |
113,332
+3,150
| +3% | +$25.6K | ﹤0.01% | 2070 |
|
|
2019
Q3 | $792K | Sell |
110,182
-7,831
| -7% | -$56.2K | ﹤0.01% | 2146 |
|
|
2019
Q2 | $938K | Buy |
118,013
+21,824
| +23% | +$258K | ﹤0.01% | 2087 |
|
|
2019
Q1 | $1.21M | Sell |
96,189
-13,607
| -12% | -$215K | ﹤0.01% | 1946 |
|
|
2018
Q4 | $2.19M | Buy |
109,796
+41,960
| +62% | +$971K | ﹤0.01% | 1587 |
|
|
2018
Q3 | $1.93M | Sell |
67,836
-200
| -0.3% | -$4.77K | ﹤0.01% | 1682 |
|
|
2018
Q2 | $1.43M | Buy |
68,036
+10,113
| +17% | +$191K | ﹤0.01% | 1853 |
|
|
2018
Q1 | $825K | Buy |
57,923
+4,370
| +8% | +$62.6K | ﹤0.01% | 2026 |
|
|
2017
Q4 | $659K | Sell |
53,553
-921
| -2% | -$13K | ﹤0.01% | 2123 |
|
|
2017
Q3 | $970K | Buy |
54,474
+8,351
| +18% | +$172K | ﹤0.01% | 1992 |
|
|
2017
Q2 | $1.17M | Buy |
46,123
+28,090
| +156% | +$676K | ﹤0.01% | 1864 |
|
|
2017
Q1 | $402K | Buy |
18,033
+845
| +5% | +$16.2K | ﹤0.01% | 2351 |
|
|
2016
Q4 | $254K | Buy |
17,188
+531
| +3% | +$10.5K | ﹤0.01% | 2570 |
|
|
2016
Q3 | $410K | Buy |
16,657
+640
| +4% | +$15K | ﹤0.01% | 2310 |
|
|
2016
Q2 | $308K | Buy |
16,017
+4,007
| +33% | +$55K | ﹤0.01% | 2517 |
|
|
2016
Q1 | $127K | Buy |
12,010
+455
| +4% | +$4.7K | ﹤0.01% | 2854 |
|
|
2015
Q4 | $140K | Buy |
+11,555
| New | +$170K | ﹤0.01% | 2893 |
|
Other funds holding EVH
CCM
RF
EC
RhumbLine Advisers's EVH Position: Q2 2026 in Review
RhumbLine Advisers increased its Evolent Health (EVH) stake by 3.4% in Q2 2026, buying an estimated $20.1K and bringing the position to 157,823 shares worth $855K. The position accounts for ﹤0.01% of the portfolio, ranked #2415.
RhumbLine Advisers first reported a position in EVH in Q4 2015 and has held it in 43 quarters since. The position peaked at $5.45M in Q1 2024. 199 funds tracked by Wall St. Rank hold EVH as of Q2 2026.
- RhumbLine Advisers held 157,823 shares of Evolent Health worth $855K as of Q2 2026.
- RhumbLine Advisers bought 5,253 Evolent Health shares in Q2 2026, an estimated $20.1K.
- Evolent Health made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2415 holding.
- RhumbLine Advisers first reported a position in Evolent Health in Q4 2015 and has held it in 43 quarters since.
- RhumbLine Advisers's Evolent Health position peaked at $5.45M in Q1 2024.
- 199 funds tracked by Wall St. Rank held Evolent Health as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.